Compare Gilead Sciences, Inc. (GILD) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Gilead Sciences, Inc. trades at $149.71 (market cap $182.40B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $214.68 (market cap $39.15B). The key difference: Gilead Sciences, Inc. is far larger — about 4.7× TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 110 Days on average.
| GILD | TTWO | |
|---|---|---|
Market Cap | $182.40B | $39.15B |
Volume | 4,469,821 | 2,708,429 |
Sector | Health | Technology |
52-Week High | $155.80 | $262.29 |
52-Week Low | $116.74 | $189.69 |
Typical Hold Time | 111 Days | 110 Days |
Enterprise Value | $205.46B | $40.27B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Take-Two Interactive trades at $204.01, up 0.73% with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth to $5.63B but faces profitability challenges with a -79.51% net margin. Analyst consensus remains strongly bullish with a $292.30 price target, supported by GTA VI's confirmed November 2026 launch. Cash flow improved significantly to $457M in 2025, though debt-to-asset ratio rose to 39.87%.
The stock presents a high-risk, high-reward opportunity with GTA VI as the primary catalyst. While current fundamentals show losses, the 79% buy rating reflects optimism for the upcoming release. Key risks include execution on the major title launch, competitive pressure, and the company's elevated debt levels. Near-term performance will likely hinge on pre-launch momentum and Q3 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
